Email alerts

Subscribe to our mailing list


Since Tri-Solfen® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW


Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Canada Humans Granted


Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.


Look after sheep welfare or pay the price, warns Modiano

December 22, 2015

One of the world’s largest wool- buying and processing companies wants Australian farmers to be forced into using pain relief when performing animal husbandry operations on sheep.

Modiano chief executive Laurence Modiano, whose company is one of the top 10 buyers of Australian merino wool, has asked federal Agriculture Minister Barnaby Joyce to legislate for mandatory spray anaesthetics and pain killers to be used by all woolgrowers when they tail dock, castrate or mules their lambs and young sheep.

London-based Mr Modiano, who sells fine wool to many of Europe’s leading fashion houses, clothes and department stores such as M & S, Hugo Boss, Gap, Next and H & M, told Mr Joyce in a letter yesterday that for some brands, Australian merino wool has become a “no-go” purchase.

He warned a lack of action on key animal welfare issues concerning consumers, including the contentious practice of lamb mulesing and tail removal without pain relief, had seen commercial requests for wool from non-mulesed sheep or grown compliant with such changed community attitudes jump 50 per cent in the past year.

“The wool industry can no longer afford the slightest whiff of association with animal pain,” Mr Modiano said.

“A failure to make pain relief mandatory for all on-farm surgery is only going to speed up this trend; (such legislation) would send a clear message to the international consumer that Australia is serious about animal welfare.’’

Mr Joyce said last night he would respond “in due course’’.

But he said each state was ultimately responsible for domestic animal welfare, although draft animal welfare guidelines — which Mr Modiano pointed out were contradictory about mulesing and pain relief — were agreed to by all state agriculture ministers.

In 2004, the Australian wool industry agreed to phase out by 2010 the contentious practice of mulesing — when wrinkled skin is sliced from a young sheep’s bottom to make it less susceptible to potentially deadly flystrike for the rest of its life.

But in 2009, wool grower body Australian Wool Innovation reneged on its self-imposed deadline, claiming mulesing was essential, that no alternatives were available, and that mandatory pain relief was too costly.

The latest data from the Australian Wool Exchange show that about half the 1.6 million bales of wool sold annually in Australia have a grower statement attached declaring the mulesing status of the flock from which the wool came.

These figures show that at least 29 per cent of the national clip, or 464,000 bales of wool, in 2014-15 came from sheep that had not been mulesed, or were mulesed using pain relief and anaesthetic, a much higher proportion than just a year ago.

With wool prices at their best levels for four years — and for some types of superfine wool at prices not seen since the wool crash of the 1990s — a small premium is also being paid by global buyers at Australian auctions for wool from non-mulesed flocks.